MoonLake Immunotherapeutics (MLTXN.MX)
- Previous Close
956.08 - Open
0.00 - Bid --
- Ask --
- Day's Range
1,074.20 - 1,074.20 - 52 Week Range
1,074.20 - 1,074.20 - Volume
0 - Avg. Volume
2,300 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 8, 2025 - May 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
www.moonlaketx.com100
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: MLTXN.MX
View MorePerformance Overview: MLTXN.MX
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MLTXN.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MLTXN.MX
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.81%
Return on Equity (ttm)
-25.08%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-118.94M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
448.03M
Total Debt/Equity (mrq)
0.62%
Levered Free Cash Flow (ttm)
-92.06M